Tech Company Financing Transactions
Xeltis Funding Round
Xeltis secured a $34 million Series D funding round on 2/21/2023. Investors included DaVita Venture Group, EQT Life Sciences and Grand Pharmaceutical.
Transaction Overview
Company Name
Announced On
2/21/2023
Transaction Type
Venture Equity
Amount
$34,024,000
Round
Series D
Proceeds Purpose
This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world's most advanced restorative cardiovascular devices.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
De Lismortel 31
Eindhoven, 5612AR
The Netherlands
Eindhoven, 5612AR
The Netherlands
Phone
Website
Email Address
Overview
Xeltis is a clinical-stage medical device company with the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis' devices naturally evolve into living blood vessels or heart valves, when colonized by patient's own tissue.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eliane Schutte
Chief Financial Officer
Alexander Goemans
Chief Technical Officer
Martijn Cox
Vice President
Paulo Neves
Browse more venture capital transactions:
Prev: 2/21/2023: Replicate venture capital transaction
Next: 2/21/2023: Xolo venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs